Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

Diabetes Care

Volumn 38, Issue 10, 2015, Pages 1975-1985

  Wherrett, Diane K ^a   Chiang, Jane L ^b   Delamater, Alan M ^c   Dimeglio, Linda A ^d   Gitelman, Stephen E ^e   Gottlieb, Peter A ^f   Herold, Kevan C ^g   Lovell, Daniel J ^h   Orchard, Trevor J ⁱ   Ryan, Christopher M ^j   Schatz, Desmond A ^k   Wendler, David S ^l   Greenbaum, Carla J ^m  

^a UNIVERSITY OF TORONTO   (Canada)

^b AMERICAN DIABETES ASSOCIATION   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m Diabetes Research Program   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C PEPTIDE; HEMOGLOBIN A1C; INSULIN; ORPHAN DRUG; OTELIXIZUMAB; RITUXIMAB; TEPLIZUMAB; THYMOCYTE ANTIBODY; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

AGE; ARTICLE; CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONSENSUS DEVELOPMENT; DIABETIC KETOACIDOSIS; DISEASE COURSE; DRUG EFFICACY; GLYCEMIC CONTROL; GOVERNMENT REGULATION; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MULTICENTER STUDY (TOPIC); PREVALENCE; QUALITY OF LIFE; RESEARCH ETHICS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; ADULT; BLOOD; CHILD; COGNITION DISORDERS; COMPLICATION; CONSENSUS; COST OF ILLNESS; DIABETES MELLITUS, TYPE 1; DRUG MANUFACTURE; LEGISLATION AND JURISPRUDENCE; MEDICAL ETHICS; METABOLISM; PROCEDURES; SECRETION (PROCESS); TREATMENT OUTCOME;

ADULT; AGE FACTORS; CHILD; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; CONSENSUS; COST OF ILLNESS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; ETHICS, MEDICAL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ORPHAN DRUG PRODUCTION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84962406567     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1429     Document Type: Article

References (99)

1. Lawrence JM, Imperatore G, Dabelea D, et al.; SEARCH for Diabetes in Youth Study Group. Trends in incidence of type 1 diabetes among non-Hispanic white youth in the U.S., 2002- 2009. Diabetes 2014;63:3938-3945.
2. Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev 2011;27:3-13.
3. Dahlquist GG, Nyström L, Patterson CC; Swedish Childhood Diabetes Study Group; Diabetes Incidence in Sweden Study Group. Incidence of type 1 diabetes in Sweden among individuals aged 0-34 years, 1983-2007: An analysis of time trends. Diabetes Care 2011;34:1754-1759.
4. Hamman RF, Bell RA, Dabelea D, et al.; SEARCH for Diabetes in Youth Study Group. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care 2014;37:3336-3344.
5. Pettitt DJ, Talton J, Dabelea D, et al.; SEARCH for Diabetes in Youth Study Group. Prevalence of diabetes in U.S. youth in 2009: The SEARCH for Diabetes in Youth study. Diabetes Care 2014;37:402-408.
6. Imperatore G, Boyle JP, Thompson TJ, et al.; SEARCH for Diabetes in Youth Study Group. Projections of type 1 and type 2 diabetes burden in the U.S. population aged, 20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 2012; 35:2515-2520.
7. Centers for Disease Control and Prevention. 2014 National Diabetes Statistics Report [Internet]. Available from www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html. Accessed 1 March 2015.
8. Menke A, Orchard TJ, Imperatore G, Bullard KM, Mayer-Davis E, Cowie CC. The prevalence of type 1 diabetes in the United States. Epidemiology 2013;24:773-774.
9. American Diabetes Association. Standards of medical care in diabetesd2015. Diabetes Care 2015;38(Suppl.1):S5-S87.
10. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978.
11. de Beaufort CE, Swift PGF, Skinner CT, et al.; Hvidoere Study Group on Childhood Diabetes 2005. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes Care 2007;30:2245-2250.
12. Dabelea D, Rewers A, Stafford JM, et al.; SEARCH for Diabetes in Youth Study Group. Trends in the prevalence of ketoacidosis at diabetes diagnosis: The SEARCH for Diabetes in Youth Study. Pediatrics 2014;133:e938-e945.
13. Rewers A, Dong F, Slover RH, Klingensmith GJ, Rewers M. Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998-2012. JAMA 2015;313:1570-1572.
14. Brands AMA, Biessels GJ, de Haan EHF, Kappelle LJ, Kessels RPC. The effects of type 1 diabetes on cognitive performance: A metaanalysis. Diabetes Care 2005;28:726-735.
15. Tonoli C, Heyman E, Roelands B, et al. Type 1 diabetes-associated cognitive decline: A metaanalysis and update of the current literature. J Diabetes 2014;6:499-513.
16. Gaudieri PA, Chen R, Greer TF, Holmes CS. Cognitive function in children with type 1 diabetes: A meta-analysis. Diabetes Care 2008;31: 1892-1897.
17. Barnea-Goraly N, Raman M, Mazaika P, et al.; Diabetes Research in Children Network (DirecNet). Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care 2014;37:332-340.
18. Patiño-Fernández AM, Delamater AM, Applegate EB, et al. Neurocognitive functioning in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes 2010;11:424-430.
19. Schwartz DD, Axelrad ME, Anderson BJ. Neurocognitive functioning in children and adolescents at the time of type 1 diabetes diagnosis: Associations with glycemic control 1 year after diagnosis. Diabetes Care 2014;37:2475-2482.
20. Jacobson AM, Ryan CM, Cleary PA, et al.; Diabetes Control and Complications Trial/EDIC Research Group. Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: An 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort. Diabetologia 2011;54:245-255.
21. Lin A, Northam EA, Werther GA, Cameron FJ. Risk factors for decline in IQ in youth with type 1 diabetes over the 12 years from diagnosis/illness onset. Diabetes Care 2015;38:236-242.
22. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: The Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006;55: 1463-1469.
23. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: The Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 2012;61:2987-2992.
24. Groop P-H, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts allcause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658.
25. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: A report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010;53: 2312-2319.
26. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with longstanding childhood-onset type 1 diabetes. Diabetes 2010;59:3216-3222.
27. Livingstone SJ, Levin D, Looker HC, et al.; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015;313:37-44.
28. Lind M, Svensson A-M, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371:1972-1982.
29. Möllsten A, Svensson M, Waernbaum I, et al.; Swedish Childhood Diabetes Study Group; Diabetes Incidence Study in Sweden; Swedish Renal Registry. Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: A nationwide population-based cohort study. Diabetes 2010;59:1803-1808.
30. Orchard TJ, Nathan DM, Zinman B, et al.; Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45-53.
31. Nathan DM, Zinman B, Cleary PA, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005). Arch Intern Med 2009;169:1307-1316.
32. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G. Insulin resistance in insulin- dependent diabetic patients with microalbuminuria. Lancet 1993;342:883-887.
33. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: A prospective study. Diabetes 1997;46:665-670.
34. Miller RG, Secrest AM, Ellis D, Becker DJ, Orchard TJ. Changing impact of modifiable risk factors on the incidence of major outcomes of type 1 diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2013;36:3999-4006.
35. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26:832-836.
36. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63:739-748.
37. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012;35: 1436-1445.
38. De Wit M, Pouwer F, Gemke RJBJ, Delemarre-van de Waal HA, Snoek FJ. Validation of the WHO-5 Well-Being Index in adolescents with type 1 diabetes. Diabetes Care 2007;30:2003-2006.
39. Ingersoll GM, Marrero DG. A modified quality-of-life measure for youths: psychometric properties. Diabetes Educ 1991;17:114-118.
40. Varni JW, Burwinkle TM, Jacobs JR, Gottschalk M, Kaufman F, Jones KL. The PedsQL in type 1 and type 2 diabetes: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Type 1 Diabetes Module. Diabetes Care 2003;26:631-637.
41. Nieuwesteeg A, Pouwer F, van der Kamp R, van Bakel H, Aanstoot H-J, Hartman E. Quality of life of children with type 1 diabetes: A systematic review. Curr Diabetes Rev 2012;8:434-443.
42. Whittemore R, Jaser S, Chao A, Jang M, Grey M. Psychological experience of parents of children with type 1 diabetes: A systematic mixedstudies review. Diabetes Educ 2012;38:562-579.
43. Haugstvedt A, Wentzel-Larsen T, Graue M, Søvik O, Rokne B. Fear of hypoglycaemia in mothers and fathers of children with type 1 diabetes is associated with poor glycaemic control and parental emotional distress: A populationbased study. Diabet Med 2010;27:72-78.
44. Johnson SR, Cooper MN, Davis EA, Jones TW. Hypoglycaemia, fear of hypoglycaemia and quality of life in children with type 1 diabetes and their parents. Diabet Med 2013;30: 1126-1131.
45. Bott U, Mühlhauser I, Overmann H, Berger M. Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. Diabetes Care 1998;21:757-769.
46. Trento M, Trevisan M, Coppo E, et al. Diagnosis of type 1 diabetes within the first five years of life influences quality of life and risk of severe hypoglycemia in adulthood. Acta Diabetol 2014;51:509-511.
47. Valenzuela JM, Patino AM, McCullough J, et al. Insulin pump therapy and health-related quality of life in children and adolescents with type 1 diabetes. J Pediatr Psychol 2006;31:650-660.
48. Lawrence JM, Yi-Frazier JP, Black MH, et al.; SEARCH for Diabetes in Youth Study Group. Demographic and clinical correlates of diabetesrelated quality of life among youth with type 1 diabetes. J Pediatr 2012;161:201-207.e2.
49. Naughton MJ, Ruggiero AM, Lawrence JM, et al.; SEARCH for Diabetes in Youth Study Group. Health-related quality of life of children and adolescents with type 1 or type 2 diabetes mellitus: SEARCH for Diabetes in Youth Study. Arch Pediatr Adolesc Med 2008;162:649-657.
50. Hoey H, Aanstoot HJ, Chiarelli F, et al. Good metabolic control is associated with better quality of life in 2, 101 adolescents with type 1 diabetes. Diabetes Care 2001;24:1923-1928.
51. Hilliard ME, Mann KA, Peugh JL, Hood KK. How poorer quality of life in adolescence predicts subsequent type 1 diabetes management and control. Patient Educ Couns 2013;91:120-125.
52. Imayama I, Plotnikoff RC, Courneya KS, Johnson JA. Determinants of quality of life in adults with type 1 and type 2 diabetes. Health Qual Life Outcomes 2011;9:115.
53. Lloyd CE, Orchard TJ. Physical and psychological well-being in adults with type 1 diabetes. Diabetes Res Clin Pract 1999;44:9-19.
54. Watkins KW, Connell CM, Fitzgerald JT, Klem L, Hickey T, Ingersoll-Dayton B. Effect of adults' self-regulation of diabetes on quality-of-life outcomes. Diabetes Care 2000;23:1511-1515.
55. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:1964-1974.
56. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care 2015;38:989-996.
57. Orban T, Sosenko JM, Cuthbertson D, et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial- Type 1. Diabetes Care 2009;32:2269-2274.
58. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691.
59. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial- Type 1. Diabetes Care 2005;28:1068-1076.
60. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al.; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97-104.
61. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473-2479.
62. Parikka V, Näntö-Salonen K, Saarinen M, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012;55:1926-1936.
63. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066-2073.
64. Davis AK, DuBose SN, Haller MJ, et al.; T1D Exchange Clinic Network. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015; 38:476-481.
65. Lovell DJ, Ruperto N, Giannini EH, Martini A. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol 2013;9:557-563.
66. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-419.
67. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recentonset type 1 diabetes: A randomised double-blind trial. Lancet 2011;378:319-327.
68. Moran A, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Canakinumab Study Group; AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebocontrolled trials. Lancet 2013;381:1905-1915.
69. Pescovitz MD, Greenbaum CJ, Krause- Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152.
70. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-1698.
71. Herold KC, Gitelman SE, Ehlers MR, et al.; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62: 3766-3774.
72. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608.
73. Hagopian W, Ferry RJ Jr, Sherry N, et al.; Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: Two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013;62:3901-3908.
74. Gitelman SE, Gottlieb PA, Rigby MR, et al.; START Study Team. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013;1:306-316.
75. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Proteǵe study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378:487-497.
76. U.S. Food and Drug Administration. Pediatric Product Development [Internet]. Available from http://www.fda.gov/Drugs/DevelopmentApproval-Process/DevelopmentResources/ucm049867.htm Accessed 2 June 2015.
77. European Medicines Agency. Paediatric- Medicine Development [Internet]. Available from http://www.ema.europa.eu/ema/index.jsp?curl5pages/regulation/general/general-content-000023.jsp. Accessed 3 June 2015.
78. European Medicines Agency. Paediatric Regulation [Internet]. Available from http://www.ema.europa.eu/ema/index.jsp?curl5pages/regulation/document-listing/document-listing-000068.jsp&mid5WC0b01ac0580025b8b. Accessed 2 June 2015.
79. European Medicines Agency. Guideline on Clinical Investigation ofMedicinal Products in the Treatment or Prevention of Diabetes Mellitus [Internet]. Available from http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500129256.pdf Accessed 2 June 2015.
80. U.S. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention [Internet]. Available from http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf Accessed 2 June 2015.
81. U.S. Food and Drug Administration. Designating an Orphan Product: Drugs and Biological Products [Internet]. Available from http://www.fda.gov/ForIndustry/DevelopingProductsforRare-DiseasesConditions/HowtoapplyforOrphanProduct-Designation/default.htm. Accessed 2 June 2015.
82. European Medicines Agency. Orphan Designation [Internet]. Available from http://www.ema.europa.eu/ema/index.jsp?curl5pages/regulation/general/general-content-000029.jsp&mid5WC0b01ac05800240ce Accessed 2 June 2015.
83. Institute of Medicine (US) Committee on Clinical Research Involving Children. Ethical Conduct of Clinical Research Involving Children [Internet]. Field MJ, Behrman RE, Eds. Washington, DC, The National Academies Press, 2004. Available from http://www.ncbi.nlm.nih.gov/books/NBK25557/Accessed 2 June 2015.
84. Gill D; Ethics Working Group of the Confederation of European Specialists in Paediatrics. Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr 2004;163:53-57.
85. Wendler D. Is it possible to protect pediatric research subjects without blocking appropriate research? J Pediatr 2008;152:467-470.
86. Sammons HM, Malhotra J, Choonara I, Sitar DS, Matsui D, Rieder MJ. British and Canadian views on the ethics of paediatric clinical trials. Eur J Clin Pharmacol 2007;63:431-436.
87. Wang D, Bahm AL, Seabrook JA, Sammons HM, Rieder MJ. A survey of Canadian medical student attitudes towards the ethics of pediatric clinical trials: Are they different from Canadian and British health care professionals? J Popul Ther Clin Pharmacol 2011;18:e10-e16.
88. Wendler D, Jenkins T. Children's and their parents' views on facing research risks for the benefit of others. Arch Pediatr Adolesc Med 2008;162:9-14.
89. Wendler D, Abdoler E, Wiener L, Grady C. Views of adolescents and parents on pediatric research without the potential for clinical benefit. Pediatrics 2012;130:692-699.
90. Ondrusek N, Abramovitch R, Pencharz P, Koren G. Empirical examination of the ability of children to consent to clinical research. J Med Ethics 1998;24:158-165.
91. Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol 2009;5:616-626.
92. Wallace CA, Giannini EH, Spalding SJ, et al.; Childhood Arthritis and Rheumatology Research Alliance (CARRA). Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: Time to achievement, total duration, and predictors. J Rheumatol 2014;41:1163-1170.
93. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve b-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with newonset type 1 diabetes. Diabetes Care 2010; 33:826-832.
94. Buckingham B, Beck RW, Ruedy KJ, et al.; Diabetes Research in Children Network (Direc- Net) Study Group; Type 1 Diabetes TrialNet Study Group. Effectiveness of early intensive therapy on b-cell preservation in type 1 diabetes. Diabetes Care 2013;36:4030-4035.
95. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet Lond Engl 2004;363: 925-931.
96. Knip M, Akerblom HK, Becker D, et al.; TRIGR Study Group. Hydrolyzed infant formula and early b-cell autoimmunity: A randomized clinical trial. JAMA 2014;311:2279-2287.
97. Chase HP, Boulware D, Rodriguez H, et al.; Type 1 Diabetes TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study Group. Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr Diabetes 2015;16:271-279.
98. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264.
99. Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A doubleblind, randomised controlled trial. Lancet 2008; 372:1746-1755.